NO20082203L - Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion - Google Patents

Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion

Info

Publication number
NO20082203L
NO20082203L NO20082203A NO20082203A NO20082203L NO 20082203 L NO20082203 L NO 20082203L NO 20082203 A NO20082203 A NO 20082203A NO 20082203 A NO20082203 A NO 20082203A NO 20082203 L NO20082203 L NO 20082203L
Authority
NO
Norway
Prior art keywords
escitalopram
bupropion
nervous system
central nervous
disorder
Prior art date
Application number
NO20082203A
Other languages
English (en)
Inventor
Jeffrey Jonas
Anjana Bose
Joyce Tsai
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20082203L publication Critical patent/NO20082203L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Foreliggende oppfinnelse vedrører en fremgangsmåte for behandling av en lidelse i sentralnervesystemet, slik som sinnslidelser (f.eks. alvorlig depressiv lidelse) eller en angstlidelse (f.eks. generell angstlidelse, sosial angstlidelse, posttraumatisk stresslidelse og panikklidelse) med en lavdosekombinasjon av escitalopram og bupropion.
NO20082203A 2005-10-14 2008-05-14 Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion NO20082203L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72727605P 2005-10-14 2005-10-14
US81088206P 2006-06-02 2006-06-02
US80408606P 2006-06-06 2006-06-06
PCT/US2006/060006 WO2007053796A2 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Publications (1)

Publication Number Publication Date
NO20082203L true NO20082203L (no) 2008-07-09

Family

ID=38006532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082203A NO20082203L (no) 2005-10-14 2008-05-14 Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion

Country Status (11)

Country Link
US (2) US7569605B2 (no)
EP (1) EP1954257A4 (no)
JP (1) JP2009511606A (no)
KR (1) KR20080080094A (no)
AU (1) AU2006308635A1 (no)
BR (1) BRPI0617382A2 (no)
CA (1) CA2625835A1 (no)
EA (1) EA200801081A1 (no)
IL (1) IL190831A0 (no)
NO (1) NO20082203L (no)
WO (1) WO2007053796A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP2502621A1 (en) 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
AU2010252740A1 (en) * 2009-05-26 2012-01-12 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
WO2012028834A1 (en) * 2010-09-01 2012-03-08 Marcel Petrus Maria Bartels Use of bupropion in treating sexual dysfunction
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
US20240122945A1 (en) * 2021-01-28 2024-04-18 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5656294A (en) 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
CA2366791A1 (en) 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU7405000A (en) 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
HUP0200169A3 (en) 1999-10-25 2002-11-28 Lundbeck & Co As H Method for the preparation of citalopram
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001283955B2 (en) * 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
IL158031A0 (en) * 2001-05-01 2004-03-28 Lundbeck & Co As H The use of enantiomeric pure escitalopram
AR034612A1 (es) 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
DE60217932T2 (de) 2001-07-31 2007-08-30 H. Lundbeck A/S, Valby Kristalline Zusammensetzung enthaltend Escitalopram
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
CA2483827C (en) 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
NZ540281A (en) 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
ATE433328T1 (de) 2002-12-24 2009-06-15 Immunofrontier Inc Polynukleotidhaltige impfstoffe
US7687645B2 (en) 2003-03-21 2010-03-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
AU2005271574A1 (en) * 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss

Also Published As

Publication number Publication date
EP1954257A2 (en) 2008-08-13
EP1954257A4 (en) 2009-05-20
WO2007053796A3 (en) 2007-11-29
CA2625835A1 (en) 2007-05-10
JP2009511606A (ja) 2009-03-19
WO2007053796A2 (en) 2007-05-10
BRPI0617382A2 (pt) 2017-07-11
EA200801081A1 (ru) 2008-10-30
IL190831A0 (en) 2008-12-29
US7569605B2 (en) 2009-08-04
KR20080080094A (ko) 2008-09-02
US20090264522A1 (en) 2009-10-22
US20070203231A1 (en) 2007-08-30
AU2006308635A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
BR112017015536A2 (pt) ?métodos de purificação de canabinoides, suas composições e kits?
BR112015012789A2 (pt) composição que compreende um agente de controle biológico e um inseticida
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
CO5640121A2 (es) Un metodo de tratamiento de un trastorno de la ansiedad
CR9697A (es) Procesos para la preparacion de compuestos de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1.3 dione.
NO20084490L (no) Nye forbindelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
ECSP088539A (es) MÉTODO DE UTILIZACIÓN DE b-HIDROXI-b-METILBUTIRATO
WO2022221440A8 (en) Influenza-coronavirus combination vaccines
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
NO20072035L (no) Memantin for behandling av adferdsforstyrrelser hos barn
NO20100077L (no) Behandling med alfa7-selektive ligander
DE602005020498D1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des yafa-gens
EA201101575A1 (ru) Лечение наследственной оптической (зрительной) нейропатии лебера и доминантной атрофии зрительного нерва токотриенол хинонами
NO20070391L (no) Jernsulfatbasert fosfatadsorbent
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2009061924A3 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
DE602006004186D1 (de) VERFAHREN ZUR HERSTELLUNG EINER NICHTAROMATISCHEN L-AMINOSÄURE UNTER VERWENDUNG EINES BAKTERIUMS DERRESSION DES csrA-GENS
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
WO2006037623A3 (en) New nuclear transcription factors regulators
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application